Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 60 4,5 1?
Displaying drugs 7726 - 7750 of 12027 in total
TAS-116 is under investigation in clinical trial NCT02965885 (A Study of TAS-116 in Patients With Solid Tumors).
Investigational
Matched Iupac: … 3-ethyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin ... -1-yl}benzamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors).
Investigational
Matched Iupac: … (3R,4S)-3-amino-1-[(2S)-2-aminopropanoyl]-4-[3-(dihydroxyboranyl)propyl]pyrrolidine-3-carboxylic acid …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. As of July...
Investigational
SER-100 is under investigation in clinical trial NCT01987284 (SER100 in Isolated Systolic Hypertension).
Investigational
Matched Iupac: … carbamimidamido-2-[(2S)-2-[(2S)-2-[(2S)-5-carbamimidamido-2-acetamidopentanamido]-3-(4-hydroxyphenyl) ... amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-5- ... propanamido]-3-(4-hydroxyphenyl)propanamido]pentanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]hexanamido …
2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).
Investigational
Matched Iupac: … dihydro-1H-isoindol-2-yl)methyl]-2,3,10,12-tetraazatricyclo[7.3.1.0^{5,13}]trideca-1,5,7,9(13),10-pentaen-4- …
ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).
Investigational
STX-100 is under investigation in clinical trial NCT01371305 (STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)).
Investigational
Investigational
ACT-101 is a recombinant human alpha-fetoprotein or rhAFP.
Investigational
ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
Investigational
AMG-119 are CAR-T cells targeting delta-like ligand 3 (DLL3).
Investigational
BI-1206 is a fully human immunoglobulin G1 monoclonal antibody that targets CD32b.
Investigational
BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.
Investigational
FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).
Investigational
AGT-182 is an investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and a human insulin receptor monoclonal antibody.
Investigational
EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.
Investigational
HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.
Investigational
Matched Description: … HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene …
RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene. Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
Investigational
ATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target sequence of the miR-208a
Investigational
CAM-101 is an allogeneic human platelet lysate product depleted of fibrinogen.
Investigational
MDR-101 is a CD34+ hematopoietic stem and progenitor cells with CD3+ T-cells
Investigational
AMT-101 is a recombinant human interleukin-10 fusion protein.
Investigational
OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene. It is being investigated for the treatment of X-linked chronic granulomatous disease.
Investigational
THR-184 is under investigation in clinical trial NCT01830920 (A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-acute Kidney Injury (CSA-AKI)).
Investigational
Nangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).
Investigational
Displaying drugs 7726 - 7750 of 12027 in total